Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2016. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities (PDMRs), and connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes and Transactions
The filing details the acquisition of GSK Ordinary shares on April 15, 2016, executed at a price of 1503.40 pence per share. These acquisitions resulted from the re-investment of dividends paid on April 14, 2016, on shares held within Individual Savings Accounts (ISAs). The specific transactions are as follows:
- Sir Andrew Witty (Director/PDMR): 321 shares
- Mr D S Redfern (Director/PDMR): 48 shares
- Mrs V A Whyte (Director/PDMR): 41 shares
- Lady C Witty (Connected Person of Sir Andrew Witty): 83 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the share transactions listed above.
Key Facts for Investor Verification
- Verify the share price of 1503.40 pence against market data for April 15, 2016.
- Confirm that the transactions were automatic dividend re-investments within ISAs rather than discretionary open-market purchases.
- Note that this filing contains no financial performance updates or strategic guidance for the period.